 1.3 Patients classified as high risk according to the Follicular Lymphoma International Prognostic Index FLIPI should be considered for CALGB 50102SWOG S0016 A Phase III Trial of CHOP vs CHOP Rituximab vs CHOP Iodine-131-Labeled Monoclonal Anti-B1 Antibody Tositumomab For Treatment of Newly Diagnosed Follicular Non-Hodgkins Lymphomas. 